Red-Hot Drug Stock Could Crush Shorts

The FDA approved Karyopharm's blood cancer treatment

Managing Editor
Jul 5, 2019 at 10:09 AM
facebook X logo linkedin


The shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) are up 15.9% to trade at $10.31 today, as analysts react to Wednesday's news that the company won accelerated approval from the Food and Drug Administration (FDA) for Xpovio, their treatment for blood cancer.

No fewer than six brokerages have hiked their price targets since the approval, the highest coming from H.C. Wainwright to $32 from $29. The analyst at RBC said the approval "bodes well for the drug's label expansion into a broader population." 

What a week it's been for Karyopharm stock -- on track for its best since June 2014 --  gapping higher 15.6% on Tuesday, and 36% on Wednesday after the FDA approval broke. Wednesday's surge put the shares above their 200-day moving average on a closing basis for the first time since October. And while KPTI has toppled its year-to-date breakeven point today, it is still staring at a 45% year-over-year deficit.

A short squeeze could power more gains. Short interest increased by 34% in the two most recent reporting periods to a record high 8.96 million shares. This accounts for 19% of KTPI's total available float, and almost two weeks' worth of pent-up buying power, at the stock's average pace of trading.  

On the options front, calls look to be extremely popular among traders. This is per data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which shows KPTI sporting a 10-day call/put volume ratio of 3.74. Given the amount of short interest tied up into the stock, it's possible some of this call buying could be shorts hedging against any additional upside.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI